SCHEMBL3356056

SCHEMBL3356056

Cc1ccc(-c2ccccc2)c(O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.61
BACE1 P56817 1/20 0.58
TP53 P04637 3/20 0.57
MEN1 O00255 2/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
KMT2A Q03164 2/20 0.57
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
BCL2L1 Q07817 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ESR2 Q92731 1/20 0.55
CNR2 P34972 2/20 0.53
CNR1 P21554 1/20 0.53
TRPA1 O75762 2/20 0.52
HDAC7 Q8WUI4 1/20 0.49
ALOX15 P16050 2/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
PSMB5 P28074 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25853004 0.96 ALOX5 (0.57) ALOX5BACE1TP53MEN1NPC1
SCHEMBL10068940 0.86 TRPA1 (0.56) ALOX5BACE1TP53MEN1NPC1
SCHEMBL22539594 0.85 EGFR (0.58) ALOX5BACE1TP53MEN1NPC1
SCHEMBL29035128 0.84 CNR2 (0.60) ALOX5TP53MEN1NPC1RAB9A
SCHEMBL31027246 0.84 BACE1 (0.62) ALOX5BACE1TP53MEN1NPC1
SCHEMBL4280343 0.84 BACE1 (0.62) ALOX5BACE1TP53MEN1NPC1
SCHEMBL31027234 0.83 BACE1 (0.60) ALOX5BACE1TP53MEN1NPC1
Methane SCHEMBL28999758 0.83 BACE1 (0.60) ALOX5BACE1TP53MEN1NPC1
SCHEMBL29538733 0.82 BACE1 (0.59) ALOX5BACE1TP53MEN1NPC1
SCHEMBL27754273 0.82 HPGD (0.57) ALOX5BACE1TP53MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503480-B2 Cyclic phosphazene compound having oxaphosphorin ring-containing structure FUSHIMI PHARMACEUTICAL CO., LTD. (JP) 2025-12-23 US disclosed
US-20230339994-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE FUSHIMI PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 US disclosed
US-11708530-B2 Organic ligands for templatable mesoscale nanocapsules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-07-25 US disclosed
EP-4202013-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE Fushimi Pharmaceutical Co., Ltd. (JP) 2023-06-28 EP disclosed
EP-4021431-A1 TREATMENT OR PREVENTION OF LEUKAEMIA Vestlandets Innovasjonsselskap AS (NO) 2022-07-06 EP disclosed
WO-2022019021-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE 株式会社伏見製薬所 2022-01-27 WO disclosed
US-20170145011-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMA (US) 2017-05-25 US disclosed
US-9511067-B2 Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-06 US disclosed
US-20150174127-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2015-06-25 US disclosed
US-8916565-B2 Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-23 US disclosed
US-20070179304-A1 Process for producing chroman compound MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2007-08-02 US disclosed
CN-1920666-A Photosensitive slurry SUMITOMO CHEMICAL CO (JP) 2007-02-28 CN disclosed
WO-2006117609-A2 PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS BIOPROJET (FR) 2006-11-09 WO disclosed
EP-1710239-A1 PROCESS FOR PRODUCING CHROMAN COMPOUND MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2006-10-11 EP disclosed
CN-1071110-C Antibacterial antiplaque, anticalculus oral composition COLGATE PALMOLIVE CO (US) 2001-09-19 CN disclosed
CN-1045533-C Continuous process for making a non-newtonian paste or cream like material COLGATE PALMOLIVE CO (US) 1999-10-13 CN disclosed
CN-1083700-A Make the continuation method of non newtonian type cream, white shape goods COLGATE PALMOLIVE CO (US) 1994-03-16 CN disclosed
CN-1066070-A Promote the new benzo-fused lactams that tethelin discharges MERCK & CO INC (US) 1992-11-11 CN disclosed
CN-1049606-A Antibacterium, antibiotic dental plaque, anti-calculus oral cavity composition COLGATE PALMOLIVE CO (US) 1991-03-06 CN disclosed
EP-0157652-A1 2-, 3- And 4-biphenyloxyaminoalkanes and related compounds, their preparation and uses, and pharmaceutical compositions containing them SYNTEX (U.S.A.) INC. (US) 1985-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174127-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels KCNJ2, KCNJ5, KCNJ1 ALOX5 2415/4885BACE1 3722/4885TP53 4003/4885
US-20170145011-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels KCNJ2, KCNJ5, KCNJ1 ALOX5 2415/4885BACE1 3722/4885TP53 4003/4885
US-20230339994-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE PFAS, PHOSPHO1, PAF1 ALOX5 817/4885BACE1 1578/4885TP53 2697/4885
US-11708530-B2 Organic ligands for templatable mesoscale nanocapsules EPCAM, L1CAM, ICOSLG ALOX5 1793/4885BACE1 4594/4885TP53 502/4885
US-12503480-B2 Cyclic phosphazene compound having oxaphosphorin ring-containing structure PFAS, PHOSPHO1, PAF1 ALOX5 817/4885BACE1 1578/4885TP53 2697/4885
US-20070179304-A1 Process for producing chroman compound TAF9, TAF1, CHD1 ALOX5 224/4885BACE1 2059/4885TP53 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.